Volume 21, Issue 4 (7-2017)                   ibj 2017, 21(4): 270-274 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abdollahpour-Alitappeh M, Lotfinia M, Razavi-Vakhshourpour S, Jahandideh S, Najminejad H, Sineh Sepehr K, et al . Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates. ibj. 2017; 21 (4) :270-274
URL: http://ibj.pasteur.ac.ir/article-1-1995-en.html

Background: Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates (ADCs). Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates. Methods: In the present study, we investigated the effect of various dithiothreitol (DTT) concentrations, temperature conditions, and DTT exposure times on antibody reduction. After antibody reduction, the Ellman's test and SDS-PAGE analysis were used to evaluate free thiols produced and confirm the reduction process, respectively. Results: DTT concentration seems to be a potential factor in the reduction process. Concentrations of 0.1, 1, 5, 10, 20, 50, and 100 mM DTT at 37°C for 30 minutes resulted in approximately 0.4, 1.2, 5.4, 7, 8, 8, and 8 thiols per antibody, respectively. Conclusion: Optimized site-specific conjugation can provide better process control and reproducibility for the development of disulfide-based ADCs.

Add your comments about this article : Your username or Email:

© 2021 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb